Microdosing GLP-1s: Is 0.25 mg a Maintenance Dose?

The pitch on Reddit and TikTok usually goes something like this:

Just stay at 0.25 and never titrate up. Fewer side effects, slower loss, same place eventually.

The logic sounds plausible: less drug could mean fewer side effects, and more time might make up the difference. Calling it “microdosing” makes the approach sound like an established protocol.

To test that claim, ask two questions: Which doses produced the weight-loss results people quote online, and how do US labels classify 0.25 mg?

The trend exists for good reasons

Cost is often the biggest reason. In some cash-pay arrangements, people may try to stretch medication to reduce spending, but whether a lower dose actually lowers cost depends on the product and payment route. Side effects matter too: if nausea peaked after your last increase, the next step can feel risky. And the basic idea—less drug should be easier on the body—sounds intuitive.

Those reasons are understandable. The unsupported leap is assuming that staying at a small dose will eventually produce the same result.

The STEP 1 headline came from 2.4 mg of semaglutide

STEP 1, the semaglutide obesity trial, enrolled 1961 adults and followed them for 68 weeks. Participants were randomly assigned to once-weekly semaglutide 2.4 mg or placebo; both groups also received a lifestyle intervention.

At week 68 the mean change in body weight was −14.9% with semaglutide versus −2.4% with placebo, an estimated treatment difference of −12.4 percentage points.

These are separate group outcomes, not values to add. Both groups received lifestyle intervention. The randomized between-group estimate was −12.4 percentage points. The −14.9% figure is the semaglutide-group mean, not a drug-only component that can be separated from each participant's other changes.

The responder rates come from that dose too. In STEP 1, 86.4% of the semaglutide group lost at least 5% of body weight versus 31.5% on placebo; 69.1% versus 12.0% lost at least 10%; and 50.5% versus 4.9% lost at least 15%.

Those responder rates come from participants assigned to the semaglutide 2.4 mg treatment strategy. They are not evidence for remaining at 0.25 mg.

Even at 2.4 mg, only about half of participants lost at least 15% of body weight. Responses varied widely, so dose matters without explaining every outcome.

What the dose-response trial found

A single trial put the doses side by side. SURMOUNT-1 assigned 2539 adults to once-weekly tirzepatide at 5 mg, 10 mg, or 15 mg, or to placebo, and followed them for 72 weeks.

Here are the results at week 72.

Mean weight loss was greater in each higher-dose tirzepatide group: −15.0% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg. That is a group-level dose response across these three maintenance doses, not a promise that every individual will lose more after every increase.

The 5 mg arm was the lowest tirzepatide maintenance dose tested in SURMOUNT-1. Zepbound's 2.5 mg initiation dose sits below it and was not tested as a maintenance arm in that trial.

What 0.25 mg means in US prescribing information

The US Wegovy injection prescribing information starts adults at 0.25 mg once weekly for 4 weeks. From there, the initial injection schedule increases every 4 weeks toward maintenance.

In that initial adult schedule, Wegovy's maintenance dosage is either 2.4 mg (recommended) or 1.7 mg once weekly.

The US Zepbound prescribing information sets 2.5 mg once weekly for 4 weeks as the starting dose for all indications, then states:

The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.

Zepbound's maintenance dosages for weight reduction and long-term maintenance are 5 mg, 10 mg, or 15 mg once weekly.

Both prescribing documents treat the smallest dose as a starting point. The term is initiation, not maintenance.

Why the dose goes up slowly

The Zepbound prescribing information also explains the escalation schedule: prescribers are told to follow it for all indications to reduce the risk of gastrointestinal adverse reactions. That supports escalation as a tolerability strategy; it does not establish the initiation dose as an effective maintenance dose.

STEP 1 found that nausea and diarrhea were the most common adverse events with semaglutide. They were typically temporary, mild to moderate, and eased with time.

SURMOUNT-1 likewise reported mostly mild-to-moderate gastrointestinal adverse events with tirzepatide. They occurred primarily during dose escalation. The trial included a 20-week escalation period within its 72 weeks. That timing supports careful escalation when tolerability is a problem, but it does not show that remaining at the starting dose prevents gastrointestinal events.

Two ways to slow or lower the schedule

The prescribing information already provides two ways to adjust dosing for tolerability.

Delay the next increase. If a patient doesn't tolerate a dose during escalation, the Wegovy prescribing information tells the prescriber to consider delaying dosage escalation for 4 weeks. That is a delay, not a stop.

Use a lower maintenance dose. In the initial adult injection schedule, Wegovy lists either 2.4 mg or 1.7 mg once weekly as maintenance. Zepbound tells prescribers to consider response and tolerability when choosing a maintenance dose and to consider a lower maintenance dosage if a patient cannot tolerate the current dose.

Both decisions belong with the prescriber. On the Wegovy prescribing information, 1.7 mg is a maintenance dose and 0.25 mg is an initiation dose. They serve different roles in the schedule, even if both look “low” beside 2.4 mg.

Tolerability did not change neatly with dose. In SURMOUNT-1, adverse events led 4.3%, 7.1%, and 6.2% of participants to stop treatment in the 5 mg, 10 mg, and 15 mg groups, respectively, versus 2.6% with placebo. STEP 1 measured something narrower: discontinuation due specifically to gastrointestinal events, which occurred in 4.5% of the semaglutide group and 0.8% of the placebo group. These figures are not directly comparable because the trials counted different outcomes.

What these trials do not tell us

The opposite claim—that a tiny dose does nothing—also goes beyond the evidence.

Neither trial included a starting-dose arm. STEP 1 escalated its treatment group to 2.4 mg, while SURMOUNT-1 compared 5 mg, 10 mg, and 15 mg with placebo. Neither followed participants who stayed at 0.25 mg for a year.

The evidence gap is specific: no trial discussed here measured a year at 0.25 mg. SURMOUNT-1 found greater average weight loss at its higher tested doses, but those results do not extend below 5 mg or to semaglutide.

Measuring a vial is a different decision

Everything above covers a prescriber adjusting the pace of escalation or choosing a maintenance dose within the prescribing information. People also use “low-dose” to describe something different: measuring a dose from a vial at home and deciding how much to take.

Approved presentations either deliver a labeled dose or provide instructions for withdrawing that labeled dose. Measuring a smaller, self-selected amount is a different step, and these prescribing instructions do not provide a method for creating an off-schedule dose.

Compounded products are not FDA-approved Wegovy or Zepbound and do not carry those products' prescribing information. A pharmacy may use a protocol of its own, but the STEP 1 and SURMOUNT-1 results summarized here did not test compounded products.

The warnings still apply at lower doses

Some label warnings apply regardless of dose.

Both Wegovy and Zepbound are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Zepbound carries the same contraindication. Neither prescribing document provides a lower-dose exception.

The Wegovy prescribing information states that acute pancreatitis—including fatal and nonfatal hemorrhagic or necrotizing pancreatitis—has been observed in patients treated with GLP-1 receptor agonists, including Wegovy. The warning provides no lower-dose exception; that is not the same as proving that the risk is identical at every dose.

Persistent or severe abdominal pain is not a wait-for-the-next-visit problem. Contact a healthcare provider promptly.

Cost, access, and the honest trade

In the US, microdosing often comes up because of cost. Coverage depends on the plan and indication. Manufacturer cash-pay programs and retail pharmacy prices can differ, and a number posted online may have little to do with what you would pay. Check the cost with your prescriber and pharmacy before planning around it.

Whether a lower dose lowers someone's spending depends on the product and payment route. The efficacy evidence has a separate limit. SURMOUNT-1 found less mean weight loss at 5 mg than at 10 mg or 15 mg, but it does not quantify the tradeoff below 5 mg or for semaglutide. Discuss those limits, along with expected response, with a prescriber.

If you use a telehealth service and mostly communicate through a portal, get the escalation plan in writing early. Know whom to message if side effects become hard to manage and who can authorize a dose change.

Three questions for your next appointment

• The escalation week is rough: is delaying the next step by 4 weeks an option for me?
• Would a lower maintenance dose be a better target for me, given how I've responded so far and how I'm tolerating this dose?
• At the dose I'm on now, how much weight change should I actually expect?

A lower maintenance dose can be an option under the prescribing information when you and your prescriber choose it. Staying at an initiation dose and expecting maintenance-dose results is different: the trials discussed here did not measure that outcome. That is the distinction to bring to your next appointment.

This is general information from the cited trials and US prescribing information, not a personal treatment plan. Any decision to start, stop, or change a GLP-1 belongs with the clinician who knows your history.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app